Last updated: October 5, 2026
Cognex is the former U.S. brand name for tacrine hydrochloride, the first FDA-approved drug specifically indicated for Alzheimer’s disease. Approved in 1993, tacrine established the oral acetylcholinesterase-inhibitor market but lost commercial relevance because of liver toxicity, intensive monitoring, frequent dosing, and competition from safer alternatives. FDA approval for Cognex was withdrawn in 2012 after the product was discontinued. The drug has no meaningful current U.S. branded revenue, no active U.S. exclusivity strategy, and limited commercial value outside historical or research contexts.[1][2]
What is Cognex and how did tacrine enter the Alzheimer’s market?
Cognex is an oral formulation of tacrine hydrochloride, marketed by Parke-Davis, a Warner-Lambert company later acquired by Pfizer. The FDA approved Cognex on September 9, 1993, for the treatment of mild-to-moderate Alzheimer’s disease.[1]
Tacrine inhibits acetylcholinesterase and increases cholinergic signaling in the brain. It was the first drug approved in the United States for Alzheimer’s disease, preceding donepezil, rivastigmine, and galantamine.
| Attribute |
Cognex / tacrine |
| Active ingredient |
Tacrine hydrochloride |
| Original brand |
Cognex |
| Originator |
Parke-Davis, later part of Warner-Lambert and Pfizer |
| FDA approval |
September 9, 1993 |
| Original indication |
Mild-to-moderate Alzheimer’s disease |
| Dosage form |
Immediate-release oral capsules |
| Historical strengths |
10 mg, 20 mg, 30 mg, and 40 mg |
| Dosing burden |
Multiple daily doses, generally four times daily after titration |
| Principal safety issue |
Hepatotoxicity |
| U.S. market status |
Discontinued; FDA approval withdrawn in 2012 |
| Current commercial position |
No material U.S. branded franchise |
The approval created an early market for symptomatic Alzheimer’s treatment, but the product’s commercial window was short. Donepezil, approved in 1996, offered simpler dosing and a more favorable market profile. Rivastigmine and galantamine later expanded the competitive set.[3][4]
When did Cognex lose exclusivity and commercial relevance?
Cognex lost practical exclusivity well before FDA approval was withdrawn. Its key commercial decline resulted from generic substitution, patent expiry, safety restrictions, and therapeutic displacement.
The original tacrine patent estate is now expired. Any U.S. composition-of-matter protection associated with tacrine would have expired many years ago, and no commercially relevant patent barrier remains for the active ingredient. The principal protection remaining around Cognex was regulatory and brand-related rather than patent-based.
Cognex exclusivity timeline
| Year |
Event |
Market impact |
| 1993 |
FDA approves Cognex |
Tacrine becomes the first U.S.-approved Alzheimer’s drug |
| 1996 |
FDA approves Aricept, or donepezil |
Lower-monitoring competitor gains adoption |
| 1997-1998 |
FDA expands warnings and monitoring requirements for tacrine |
Prescribing becomes more difficult |
| 2000 |
FDA approves Exelon, or rivastigmine |
Additional cholinesterase-inhibitor competition |
| 2001 |
FDA approves Razadyne, or galantamine |
Further reduces tacrine’s market position |
| 2000s |
Generic tacrine becomes available in limited settings |
Brand value erodes |
| 2012 |
FDA withdraws Cognex approval after discontinuation |
U.S. branded product exits |
FDA labeling required liver-function monitoring because transaminase elevations occurred frequently in clinical use. The label also described more serious hepatic injury risks and recommended structured dose escalation and monitoring.[2]
Tacrine’s effective commercial exclusivity therefore ended through a combination of patent expiry and clinical obsolescence. The product remained legally recognizable as an approved drug for years after it had ceased to be competitive.
What is the FDA and Orange Book status of Cognex?
Cognex no longer has an active U.S. commercial approval. FDA withdrew approval of the Cognex new drug application after the sponsor requested withdrawal following product discontinuation. The withdrawal was not treated as a withdrawal for reasons of safety or effectiveness in the relevant FDA notice.[5]
Historically, Cognex was listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. Its current commercial significance is limited because:
- The branded product is discontinued.
- The FDA approval has been withdrawn.
- No active branded exclusivity remains.
- Tacrine is not a current high-volume generic opportunity.
- The market has shifted to alternative cholinesterase inhibitors and newer Alzheimer’s therapies.
A former Orange Book listing does not create a present-day barrier to tacrine competition. Any remaining generic market would depend on manufacturing economics, supplier availability, regulatory reactivation, and clinical demand rather than patent protection.
What patents protect Cognex and tacrine?
No material active U.S. patent estate protects Cognex today. Tacrine’s original active-ingredient and formulation protections expired long ago.
Patent categories historically relevant to Cognex
Active ingredient patents
The earliest patent strategy centered on tacrine, also known as 1,2,3,4-tetrahydroacridin-9-amine. Those rights are expired. They do not prevent current manufacture of tacrine where regulatory and commercial conditions support production.
Formulation patents
Cognex was sold as immediate-release capsules in multiple strengths. Historical formulation or dosage patents, if any, are expired and do not support current market exclusivity.
Method-of-use patents
Tacrine’s Alzheimer’s indication was associated with its original regulatory approval and clinical use. Any method-of-use exclusivity tied to that indication has expired. No current method-of-use patent materially restricts Alzheimer’s treatment competition involving tacrine.
Manufacturing patents
Tacrine manufacturing processes are also unlikely to create an enforceable commercial barrier in the United States because the product has been available for decades and any early process patents would have expired. Current manufacturing barriers are more likely to involve active pharmaceutical ingredient supply, quality systems, and the economics of producing a low-demand product.
How strong is the Cognex patent estate?
The current patent estate is commercially negligible.
| Patent factor |
Current assessment |
| Active composition-of-matter protection |
None of commercial significance |
| Active formulation protection |
None of commercial significance |
| Active method-of-use protection |
None of commercial significance |
| Patent term extension |
No current relevance |
| Orange Book patent litigation |
No meaningful current activity |
| Paragraph IV exposure |
Historically possible, currently immaterial |
| Manufacturing protection |
No known current barrier with material market effect |
| Overall patent strength |
Very weak or effectively exhausted |
Cognex is not a patent-driven asset. Any investment or licensing thesis would need to rely on a new formulation, a different indication, a novel delivery system, or new clinical evidence. Those opportunities would concern a new tacrine product rather than the legacy Cognex franchise.
Which companies challenged or replaced Cognex?
The main competitive threat came from alternative Alzheimer’s medicines rather than litigation-led generic entry.
| Product |
Active ingredient |
Approval timing |
Competitive advantage over tacrine |
| Cognex |
Tacrine |
1993 |
First approved Alzheimer’s drug, but high liver-monitoring burden |
| Aricept |
Donepezil |
1996 |
Once-daily dosing and broader prescribing acceptance |
| Exelon |
Rivastigmine |
2000 |
Alternative mechanism profile and later transdermal delivery |
| Razadyne |
Galantamine |
2001 |
Alternative cholinesterase inhibitor and dosing options |
| Namenda |
Memantine |
2003 |
Different pharmacologic class for moderate-to-severe disease |
| Leqembi |
Lecanemab |
2023 |
Disease-modifying anti-amyloid therapy for eligible patients |
Donepezil became the principal commercial replacement for tacrine in the cholinesterase-inhibitor segment. Rivastigmine and galantamine added further pressure. Memantine expanded the market beyond cholinesterase inhibition, while lecanemab introduced a disease-modifying treatment category for selected patients with early Alzheimer’s disease.[3][6]
What was Cognex’s financial trajectory?
Public company filings generally did not report Cognex revenue as a standalone product line. Warner-Lambert and later Pfizer reported results at broader business-segment levels, preventing a reliable product-specific revenue series.
The financial trajectory is nevertheless clear:
- Initial launch value: Cognex held first-mover status in the U.S. Alzheimer’s market after its 1993 approval.
- Rapid competitive erosion: Donepezil and later cholinesterase inhibitors offered more convenient dosing and fewer operational burdens.
- Safety-driven decline: Frequent liver-function testing and transaminase elevations reduced physician and patient acceptance.
- Generic erosion: Patent expiry and generic availability eliminated the economic basis for maintaining a premium brand.
- Portfolio exit: The sponsor discontinued the product, and FDA approval was withdrawn in 2012.
- Residual value: Current commercial value is effectively limited to historical data, expired intellectual property, and possible research use.
Revenue exposure for Pfizer and Warner-Lambert
Cognex was never a durable major-revenue product relative to later Alzheimer’s medicines or Pfizer’s broader portfolio. Its strategic value was greater than its long-term financial value because it established a presence in a new therapeutic market but did not retain that position after competitors entered.
No reliable current revenue estimate should be assigned to Cognex. The product has no active U.S. branded sales base, and any historical sales figures would depend on company disclosures or third-party market datasets that are not consistently reported at the product level.
What generic launch risks exist for tacrine?
A generic tacrine launch would face limited patent risk but substantial commercial and regulatory risk.
Patent and Paragraph IV risk
A Paragraph IV certification would have little strategic importance today because the original patent estate is expired or commercially irrelevant. The principal challenge would not be patent litigation. It would be whether a manufacturer could support an abbreviated or full regulatory pathway for a product with limited demand and a withdrawn reference approval.
Regulatory risk
A sponsor seeking to reintroduce tacrine would need to address:
- The absence of an actively marketed reference product.
- Historical hepatotoxicity.
- Labeling and monitoring requirements.
- Bioequivalence or other product-specific requirements.
- Manufacturing and supply-chain economics.
- Physician willingness to prescribe an older, higher-risk medicine.
Commercial risk
The market would be constrained by established alternatives, including generic donepezil, rivastigmine, and galantamine. Those products have greater clinical familiarity and stronger distribution networks. A tacrine product would need a clear advantage, such as a novel formulation, lower hepatic exposure, or a new therapeutic use.
Is there biosimilar risk for Cognex?
No. Cognex is a small-molecule drug, not a biologic. Biosimilar regulation does not apply. Competitive risk comes from generic small-molecule products, alternative cholinesterase inhibitors, memantine, and newer anti-amyloid therapies.
What licensing deals and litigation affect Cognex?
No active major licensing transaction or material patent litigation involving Cognex is evident in the current commercial landscape. The historic rights moved through the corporate ownership chain from Parke-Davis to Warner-Lambert and ultimately Pfizer. Those ownership changes did not preserve a meaningful active franchise after discontinuation.
There is also no current settlement structure comparable to those surrounding major branded drugs with active patent estates. Any historical generic settlements would have limited present value because the product’s patents and market position are exhausted.
How does Cognex compare with current Alzheimer’s drugs?
Cognex is disadvantaged on efficacy positioning, safety management, dosing convenience, and commercial infrastructure.
| Dimension |
Cognex |
Current alternatives |
| Treatment role |
Symptomatic cholinesterase inhibition |
Symptomatic and disease-modifying options |
| Liver monitoring |
Significant concern |
Generally less central for common alternatives |
| Dosing |
Multiple daily doses |
Once-daily, twice-daily, or transdermal options |
| Generic availability |
Limited practical relevance |
Strong for donepezil and other agents |
| Patent protection |
Expired |
Varies by product and formulation |
| Commercial demand |
Minimal |
Established or growing by product |
| Reimbursement position |
Weak |
Better established |
| Clinical adoption |
Low |
Higher for later-approved agents |
Cognex’s historical importance does not translate into current market power. The drug is a legacy product with exhausted exclusivity and minimal commercial demand.
Key Takeaways
- Cognex is tacrine hydrochloride, the first FDA-approved Alzheimer’s drug in the United States.
- FDA approved it in 1993 and withdrew approval in 2012 after discontinuation.
- Hepatotoxicity, liver monitoring, frequent dosing, and competition drove its decline.
- Tacrine’s patent estate is expired and has no meaningful current blocking power.
- There is no current U.S. branded Cognex revenue franchise.
- Generic entry risk is low in commercial terms because demand is weak, not because of patent protection.
- Tacrine is not subject to biosimilar competition.
- A viable reintroduction would require a new formulation, new indication, or materially improved safety profile.
- Donepezil, rivastigmine, galantamine, memantine, and newer anti-amyloid therapies displaced Cognex across different segments of Alzheimer’s care.
FAQs
Is Cognex still available by prescription?
Cognex is not marketed as an active U.S. branded product. FDA withdrew its approval in 2012 after discontinuation.
Is tacrine the same as donepezil?
No. Both are acetylcholinesterase inhibitors used historically for Alzheimer’s disease, but tacrine and donepezil are different active ingredients. Donepezil replaced tacrine in much of the market because of simpler dosing and a more favorable safety profile.
Does Cognex have active Orange Book patents?
No commercially meaningful active patent protection remains for Cognex. Its historical patents have expired, and the product’s U.S. approval was withdrawn.
Could a company relaunch tacrine?
A company could pursue a new tacrine product subject to applicable FDA requirements, but commercial viability would be difficult without a differentiated formulation, lower hepatotoxicity, or a new clinical use.
Was Cognex a major Pfizer revenue product?
No reliable public product-level revenue series establishes Cognex as a major Pfizer revenue contributor. Its strategic importance came from first entry into Alzheimer’s treatment, while its long-term financial contribution was limited by competition and safety concerns.
References
-
U.S. Food and Drug Administration. (1993). Cognex (tacrine hydrochloride) capsules prescribing information. FDA.
-
U.S. Food and Drug Administration. (2005). Cognex (tacrine hydrochloride) capsules label. FDA.
-
U.S. Food and Drug Administration. (1996). Aricept (donepezil hydrochloride) approval information. FDA.
-
U.S. Food and Drug Administration. (2000). Exelon (rivastigmine tartrate) approval information. FDA.
-
U.S. Food and Drug Administration. (2012). Withdrawal of approval of a new drug application for Cognex. Federal Register.
-
U.S. Food and Drug Administration. (2023). Leqembi (lecanemab-irmb) approval announcement. FDA.
